A kind of linagliptin long-acting sustained-release microsphere and preparation method thereof

By preparing linagliptin long-acting sustained-release microspheres and using lactide-glycolic acid copolymer as a sustained-release carrier, the problems of poor drug compliance and low bioavailability of linagliptin tablets were solved, achieving long-acting sustained release and high drug loading, which is suitable for industrial production.

CN116407509BActive Publication Date: 2024-11-15UNIV OF JINAN
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310323287.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-30
Publication Date
2024-11-15
Estimated Expiration
2043-03-30

AI Technical Summary

Technical Problem

Existing linagliptin tablets and orally disintegrating tablets have problems with poor medication compliance and low bioavailability, and are not suitable for children, the elderly or patients with difficulty swallowing. In addition, ordinary fillers cannot improve their bitterness, and diabetic patients cannot use sugar fillers.

Method used

A biodegradable lactide-glycolic acid copolymer was used as a sustained-release carrier to prepare linagliptin long-acting sustained-release microspheres via an O/W monoemulsion-solvent evaporation method. The microspheres have a core-shell structure, and the drug is evenly distributed within the microspheres, resulting in stable release, masking unpleasant drug odor, and improving stability.

Benefits of technology

It achieves long-term sustained release of drugs, reduces the frequency of administration, improves patient compliance and medication adherence, has a drug release cycle of up to one month, high drug loading and encapsulation efficiency, and is suitable for industrial production due to its universal equipment and simple process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116407509B_ABST
    Figure CN116407509B_ABST
Patent Text Reader

Abstract

The present invention discloses a linagliptin long-acting sustained-release microsphere and a preparation process thereof. The present invention adopts an emulsification-solvent volatilization method (O / W) to prepare the linagliptin long-acting sustained-release microsphere, which has a simple preparation process and is easy to scale up. The prepared microsphere has good safety, high drug loading and encapsulation efficiency, uniform particle size distribution, smooth surface, and can sustain long-term stable release without obvious burst release.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical preparations and relates to a linagliptin long-acting sustained-release microsphere and a preparation process thereof. Background Art

[0002] Currently, one in every 11 adults in the world suffers from diabetes, and about 90% of these patients suffer from type 2 diabetes (T2DM). Type 2 diabetes, also known as non-insulin-dependent diabetes, has a high prevalence, insidious onset, and no obvious early symptoms, leading to a large increase in undiagnosed diabetes cases, the general aging of patients, and high treatment costs. The development of T2DM involves a variety of pathological and physiological mechanisms. In addition, with the influence of changes in dietary structure, environmental pollution, and life pressure, the incidence of T2DM and its complications continues to rise, which has become the main cause of disability and death in T2DM patients.

[0003] According to data from the International Diabetes Federation (IDF), the number of adult diabetics worldwide will reach 537 million in 2021. As the country with the largest number of diabetics in the world, my country has seen an increase of 56% in the number of diabetics from 90 million to 141 million in the past 10 years (2011-2021). However, the current global diabetes diagnosis rate is less than 45%, and the treatment rate is less than 50%. As the diagnosis and treatment rates of diabetes gradually increase, the patient pool will see more expansion.

[0004] At present, the domestic diabetes market is still dominated by insulin and its analogs, followed by traditional oral drugs such as biguanides and α-glucosidase inhibitors. However, new drugs such as DPP-4 inhibitors have not been fully promoted in the Chinese market due to their late entry into the market, accounting for only about 10% of the diabetes drug market, and there is a lot of room for improvement. Linagliptin compound is the main ingredient of the drug with the trade name Linagliptin Tablets; it was first developed by Boehringer Ingelheim in Germany, launched in the United States in June 2011, approved for marketing in Europe in June of the same year, and approved by the China Food and Drug Administration in April 2013, and approved for marketing in China.

[0005] Clinically, the drug synthesized from this compound is a new and effective selective dipeptidyl peptidase-4 (DPP-4) inhibitor, which can be used to treat type 2 diabetes. Linagliptin is a dipeptidyl peptidase inhibitor that reduces the inactivation of GLP-1 in the body by inhibiting DPP-4, increases the level of endogenous GLP-1, and promotes the rapid release of intestinal insulin in the blood. The ultimate goal is to reduce glucagon in the body and meet the blood sugar lowering needs of diabetic patients. Linagliptin has the advantages of not needing to adjust the dosage according to the patient's liver and kidney function status, stable blood sugar lowering, not easy to induce hypoglycemia, fewer gastrointestinal adverse reactions, and is more suitable for the elderly and patients with liver and kidney damage.

[0006] Currently, most of the linagliptin dosage forms on the market are tablets, and the drugs on the market need to be used in combination with metformin and sulfonylurea drugs. Linagliptin tablets (Otangning) need to be taken every day, and they need to be taken for more than 36 months. The long cycle often leads to missed doses and overdose, which brings great inconvenience to patients. Therefore, it is very important to develop sustained-release microspheres.

[0007] Linagliptin, chemical name is 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butynyl-1)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione. Its chemical structure is as follows:

[0008]

[0009] Patent CN 110151719 A discloses a process for preparing linagliptin tablets. The preparation process is to mix linagliptin, mannitol, starch and pregelatinized starch in a wet granulator, and then add copolyvidone solution for wet granulation. Then the obtained granules are moved to a fluidized bed for drying, and the moisture in the granules is measured with a halogen rapid moisture meter, and then the dried granules are moved to a three-dimensional motion mixer and magnesium stearate is added for total mixing; finally, linagliptin tablets are obtained by a tablet press. However, in clinical use, for some patients, especially children, the elderly or other patients with dysphagia, ordinary tablets greatly reduce the patient's compliance with medication. In addition, the solubility of ordinary oral tablets is not high, and the bioavailability is low, only about 30%.

[0010] Patent CN 105853382 A discloses a preparation of a linagliptin orodisintegrating tablet, wherein the method is to prepare linagliptin with erythritol, a disintegrant, a lubricant and a flavoring agent to obtain linagliptin orodisintegrating tablets. The orodisintegrating tablets prepared by the method have good taste, are easy to take, do not require water, and can be taken anytime and anywhere. However, there are certain difficulties in making linagliptin into orodisintegrating tablets: linagliptin tastes bitter, and ordinary fillers cannot effectively improve its taste; although sugars such as lactose and sucrose have a better taste, they are not suitable for diabetic patients, so there is no report of linagliptin orodisintegrating tablets.

[0011] Patent CN 105878219 B discloses a linagliptin oral film and its preparation process. The oral fast-dissolving film is made of linagliptin, erythritol, hydroxypropyl methylcellulose, hydroxypropyl cellulose, a plasticizer and a flavoring agent. However, because linagliptin tastes bitter, ordinary fillers cannot effectively improve its taste; and although sugars such as lactose and sucrose have a better taste, they are not suitable for diabetic patients. Therefore, there is no report on linagliptin oral fast-dissolving film. Summary of the invention

[0012] In view of the shortcomings of the prior art, the present invention discloses a linagliptin long-acting sustained-release microsphere and a preparation method thereof. The linagliptin long-acting sustained-release microsphere uses a biodegradable polymer material lactide-glycolide copolymer as a sustained-release carrier, slowly releases the drug through degradation of the carrier material, reduces the frequency of administration, and improves the patient's compliance and medication adherence.

[0013] The inventors have conducted in-depth research on the existing technical status and found through a large number of experimental results that the above-mentioned purpose can be achieved by adopting the following technical scheme, thereby completing the present invention. The technical scheme of the present invention is as follows: a long-acting sustained-release microsphere of linagliptin, comprising 10%-30% of the weight of the linagliptin sustained-release microsphere of linagliptin drug, and 70%-90% of the weight of the linagliptin sustained-release microsphere of lactide-glycolide copolymer.

[0014] The linagliptin long-acting sustained-release microspheres have high encapsulation efficiency and drug loading, uniform particle size, smooth surface and stable release, and the release period can be as long as about one month.

[0015] The linagliptin long-acting sustained-release microspheres are selected from lactide-glycolide copolymers whose terminal groups are -COOH groups, and the molar ratio of lactide to glycolide is 90:10 to 10:90, preferably, the molar ratio of lactide to glycolide is 75:25 to 50:50; more preferably, the molar ratio of lactide to glycolide is 75:25, 65:35 or 50:50. The molecular weight of the lactide-glycolide copolymer is 5000 to 80000 Daltons, preferably, the molecular weight of the lactide-glycolide copolymer is 10000 to 50000 Daltons.

[0016] The particle size range of the linagliptin long-acting sustained-release microspheres is 20-200 μm, and preferably, the particle size range of the linagliptin sustained-release microspheres is 40-150 μm.

[0017] The present invention provides a method for preparing linagliptin long-acting sustained-release microspheres, and the specific steps of the preparation process are as follows:

[0018] (1) dissolving linagliptin and lactide-co-glycolide copolymer in an organic solvent to form a clear and transparent solution as an oil phase;

[0019] (2) preparing a certain concentration of polyvinyl alcohol (PVA) aqueous solution as the water phase;

[0020] (3) mixing the solution obtained in step (1) with the PVA solution obtained in step (2), and preparing an O / W emulsion by high-speed shear emulsification;

[0021] (4) adding dipotassium hydrogen phosphate solution to the emulsion obtained in step (3), stirring at a low speed, and volatilizing and removing the organic solvent; collecting after solidification, washing, and freeze-drying to obtain the product.

[0022] The organic solvent in step (1) is selected from one or a mixture of two or more of dichloromethane (DCM), benzyl alcohol, N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), and methanol, preferably dichloromethane (DCM) and dimethyl sulfoxide (DMSO);

[0023] The concentration of polyvinyl alcohol in step (2) is 0.1% to 2% (w / v), preferably 0.5% to 1% (w / v);

[0024] The temperature of the polyvinyl alcohol in step (2) is 0 to 30° C., preferably 5 to 25° C.;

[0025] In step (3), the volume ratio of the organic solvent to the polyvinyl alcohol solution is 1:50 to 1:300, preferably 1:50 to 1:200;

[0026] The concentration of the dipotassium hydrogen phosphate solution in step (4) is 0.02 mol / L to 0.2 mol / L, preferably 0.05 mol / L to 0.2 mol / L.

[0027] Compared with the prior art, the core innovations of the present invention are as follows:

[0028] 1. The present invention is directed to the advantages that dichloromethane has strong dissolving ability, good volatility and low residual amount, can dissolve linagliptin drugs and lactide-glycolide copolymers, and has high encapsulation efficiency and drug loading of the prepared microspheres. Therefore, dichloromethane is preferably used as the organic solvent for preparing linagliptin long-acting sustained-release microspheres.

[0029] 2. The present invention adopts the O / W single emulsification-solvent evaporation method to prepare the long-acting sustained-release microspheres of linagliptin. The microspheres prepared by the O / W single emulsification-solvent evaporation method have high drug loading and encapsulation rate, high yield, reduced drug particle size, avoidance of drug particle aggregation, and stable release, which can greatly prolong the drug action time, reduce the number of drug administrations, and improve patient compliance and medication compliance; the process flow of the O / W method has the characteristics of universal equipment, simple process, short time consumption, low solvent residue, easy to scale up production, etc., and has good industrial application.

[0030] 3. The microspheres prepared by the emulsification (O / W)-solvent evaporation method of the present invention have a unique core-shell structure, the drug is evenly distributed in the microspheres, the drug burst release is small, and the stable release of the drug is achieved.

[0031] 4. The present invention microspherizes the drug, which can not only cover up the bad smell of the drug, but also improve the stability of the drug, prevent the drug from being inactivated in the stomach or reduce the irritation of the drug to the stomach, reduce the number of medications and improve patient compliance. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 : Optical microscopic image of the linagliptin long-acting sustained-release microspheres prepared in Example 1 before solidification;

[0033] Figure 2 : Optical microscopic image of the linagliptin long-acting sustained-release microspheres prepared in Example 1 after solidification;

[0034] Figure 3 : The finished product picture of the linagliptin long-acting sustained-release microspheres prepared in Example 1 after freeze-drying and collection;

[0035] Figure 4 : Scanning electron micrograph of the linagliptin long-acting sustained-release microspheres prepared in Example 1;

[0036] Figure 5 : HPLC chromatogram of the linagliptin long-acting sustained-release microspheres prepared in Example 1;

[0037] Figure 6 : HPLC chromatogram of the linagliptin long-acting sustained-release microspheres prepared in Example 1;

[0038] Figure 7 : In vitro release curve of the linagliptin long-acting sustained-release microspheres prepared in Example 3;

[0039] Figure 8 : In vitro release curve of the linagliptin long-acting sustained-release microspheres prepared in Example 6;

[0040] Fig. 9 : In vitro release curve of the linagliptin long-acting sustained-release microspheres prepared in Example 9. DETAILED DESCRIPTION

[0041] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings. It should be understood that these descriptions are only exemplary and are not intended to limit the scope of the present invention. In addition, in the following description, the description of well-known structures and technologies is omitted to avoid unnecessary confusion of the concept of the present invention.

[0042] The microspheres described in the present invention are microspheres in a broad sense, which refer to tiny particles formed by dissolving / dispersing drugs in polymer materials. Their form is not limited to spheres, and can be irregular, polyhedral, elliptical, rod-shaped, pellet-shaped, etc.

[0043] The lactide-glycolide copolymer used was from Evonik Specialty Chemicals Co., Ltd.

[0044] The dimethyl sulfoxide, dichloromethane, and methanol used were from Tianjin Fuyu Fine Chemical Co., Ltd.;

[0045] The PVA used was sourced from Shanghai Yingjia Industrial Development Co., Ltd.

[0046] Embodiment one:

[0047] Preparation of Linagliptin Long-acting Sustained-release Microspheres

[0048] S1 weighed 50.9 mg of linagliptin and 150.8 mg of lactide-glycolide copolymer (50:50, molecular weight 18,000), added 0.6 ml of dichloromethane, and dissolved to obtain a clear solution as the oil phase;

[0049] S2 prepares 250 ml of 0.5% PVA solution, controls the temperature at 20-25°C, as the aqueous phase;

[0050] S3 disperses the oil phase into the water phase under the action of high-speed shearing, with a rotation speed of 1200 rpm and shearing for 10 s to prepare an O / W emulsion;

[0051] S4: slowly add 50 ml of 0.2 mol / L potassium dihydrogen phosphate solution to the emulsion, stir at a low speed for 4 hours to solidify, and evaporate to remove the organic solvent dichloromethane; after solidification, wash, freeze-dry, and collect by sieving.

[0052] Microsphere morphology observation:

[0053] 10 mg of the linagliptin long-acting sustained-release microspheres prepared in Example 1 were uniformly dispersed on the conductive glue, and after gold spraying at a voltage of 10 KV, the appearance of the microspheres was observed using a scanning electron microscope (SEM, Coxem, Korea). It can be seen that the microspheres obtained in this study have a rounded shape and a smooth surface. The observation results are shown in Figure 4 .

[0054] The preparation methods of Examples 2 to 14 are the same as those of Example 1, except for the drug loading, the specifications and concentration of the lactide-co-glycolide copolymer, the aqueous phase concentration, the curing temperature and the concentration of the added dipotassium hydrogen phosphate. The specifics of Examples 1 to 8 are shown in Table 1.

[0055] Table 1 Specifications of PLGA in Examples 1-10

[0056]

[0057]

[0058] Note: In the PLGA model, 5050, 6535, and 7525 indicate that the lactic acid / glycolic acid (LA / GA) ratio in the polymer material is 50:50, 65:35, and 75:25, respectively.

[0059] Taking the PLGA specifications of Example 3 as an example, Examples 11 to 14 used the method of changing a single factor to explore the effects of other factors on the linagliptin long-acting sustained-release microspheres. See Table 2 for details.

[0060] Table 2 Influencing factors of Examples 3, 11-14

[0061]

[0062] Experimental Example 1 Determination of drug loading and encapsulation efficiency of linagliptin long-acting sustained-release microspheres

[0063] Test solution: weigh about 20 mg of linagliptin microspheres, place in a 50 ml volumetric flask, add 2 ml DMSO to dissolve, ultrasonicate for about 5 min, after complete dissolution, add 0.01 mol / L HCL to make up to volume, shake well, dilute ten times, shake well, filter (PTFE, 0.22 μm, 25 mm), discard 3 ml, and take the filtrate.

[0064] Reference solution: weigh about 20 mg of linagliptin, place in a 100 ml volumetric flask, add 2 ml of methanol to dissolve, make up to volume with water, shake well, dilute ten times, filter (PTFE, 0.22 μm, 25 mm), discard 3 ml, and take the filtrate.

[0065] Drug loading (%) = (mass of drug contained in microspheres) / (total mass of microspheres) * 100%

[0066] Encapsulation efficiency (%) = (actual drug loading of microspheres) / (theoretical drug loading of microspheres) * 100%

[0067] Encapsulation efficiency formula:

[0068]

[0069] W 游离 —Amount of free drug, mg;

[0070] W 总 —Total amount of drug, mg;

[0071] The encapsulation efficiency of the linagliptin long-acting sustained-release microspheres prepared in Examples 1 to 14 was determined by high performance liquid chromatography (HPLC).

[0072] Octadecylsilane bonded silica gel column

[0073] Liquid phase conditions: mobile phase 50mmol / L potassium dihydrogen phosphate: acetonitrile = 72:28.

[0074] The detection wavelength was 294 nm, the column temperature was 35 °C, and the flow rate was 1 ml / min.

[0075] Table 3 Drug loading and encapsulation efficiency results of Examples 1-14:

[0076]

[0077]

[0078] As can be seen from Table 3, with the increase of drug loading, the encapsulation efficiency gradually decreased, and with the increase of PLGA molecular weight, the encapsulation efficiency gradually increased. PLGA concentration and K2HPO4 have a great influence on the long-acting sustained-release microspheres of linagliptin.

[0079] Experimental Example 2 In vitro release experiment of linagliptin long-acting sustained-release microspheres

[0080] Experimental samples: linagliptin long-acting sustained-release microspheres prepared in Example 3, Example 6, and Example 9.

[0081] Experimental method: Accurately weigh a certain amount of linagliptin long-acting sustained-release microsphere sample into a 50ml centrifuge tube with a lid, add 30ml PBS buffer, put it into a 37℃ constant temperature shaker, and reciprocate at a frequency of 100rpm. Take it out at the specified time point, let it stand or centrifuge, take 5ml of supernatant and filter (PTFE, 0.22μm, 25mm), discard 3ml, and take the filtrate. And add an equal volume of fresh PBS buffer. The reference solution is the same as in Experimental Example 1, and the release filtrate concentration is calculated by the external standard method.

[0082] The cumulative release rate is calculated as follows:

[0083]

[0084] In the formula:

[0085] V0—volume of release medium used, ml;

[0086] C t —The concentration of the drug contained in the release medium measured at the sampling time point, mg / ml;

[0087] V—volume of each sampling, ml;

[0088] W—total weight of microspheres input, mg;

[0089] X—drug loading of microspheres (%).

[0090] like Figure 7 , Figure 8 , Fig. 9It can be seen from the release curve of linagliptin long-acting sustained-release microspheres that the burst release of linagliptin long-acting sustained-release microspheres is not large, and it shows a trend of gradually accelerating. The release rate of the microspheres will be affected by factors such as the specifications and molecular weight of PLGA, and the proportion of solvents. It is well known that a large molecular weight of the PLGA used will lead to slow drug release from the drug-loaded microspheres. Under the same viscosity and molecular weight, PLGA with a specification of 50:50 will release faster than PLGA with specifications of 65:35 and 75:25. Combined with multiple factors such as drug loading, encapsulation efficiency and release, after multiple repetitive experimental verifications, the present invention finally determined that the optimal prescription was PLGA specifications of 50:50 31,000, and a drug loading of 25% of linagliptin long-acting sustained-release microspheres, with a release period of about 35 days, and safe and stable release.

Claims

1. A linagliptin long-acting sustained-release microsphere, characterized in that: The microspheres contain linagliptin and lactide-glycolide copolymer; wherein, relative to the total weight of the microsphere composition, the content of linagliptin is 10%-30%, and the content of lactide-glycolide copolymer is 70%-90%; the specification of PLGA is 50:50 3.10,000; The preparation method of the linagliptin long-acting sustained-release microspheres comprises the following steps: (1) dissolving linagliptin and lactide-co-glycolide copolymer in an organic solvent to form a clear and transparent solution as an oil phase; (2) preparing a polyvinyl alcohol aqueous solution of a certain concentration as the water phase; (3) mixing the solution obtained in step (1) with the PVA solution obtained in step (2), and preparing an O / W emulsion by high-speed shear emulsification; (4) slowly adding dipotassium hydrogen phosphate solution to the emulsion obtained in step (3), stirring at a low speed, and volatilizing and removing the organic solvent; after solidification, collecting, washing, and freeze-drying to obtain; The organic solvent in step (1) is selected from one or a mixture of two or more of dichloromethane, benzyl alcohol, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide and methanol; The concentration of the polyvinyl alcohol solution in step (2) is 0.1%~2% (w / v); the temperature of the polyvinyl alcohol is 0~30°C; the volume ratio of the organic solvent to the polyvinyl alcohol solution in step (3) is 1:50~1:300; the concentration of the potassium hydrogen phosphate solution in step (4) is 0.02mol / L~0.2mol / L.

2. The linagliptin long-acting sustained-release microspheres according to claim 1, characterized in that: The terminal group of the selected lactide-glycolide copolymer is a -COOH group.

3. The linagliptin long-acting sustained-release microspheres according to claim 1, characterized in that: The particle size range of the prepared microspheres is 20μm~200μm.

4. Use of the microsphere composition according to any one of claims 1 to 3 in the preparation of a drug for treating diabetes.